BioMed Research International / 2015 / Article / Tab 1

Research Article

Attention Deficit Hyperactivity Disorder Symptoms, Comorbidities, Substance Use, and Social Outcomes among Men and Women in a Canadian Sample

Table 1

Characteristics of CAMH Monitor survey respondents who screened positively and negatively for symptoms on the Adult ADHD Self-Report Scale-V1.1 January 2011–December 2012.

ADHD +ADHD −
ScreenScreen
%%

Age
 18–24 265.445894.6<0.001
 25–44 543.9134696.1
 45–64 493.6132696.4
 ≥65 40.666699.4
Gender
 Female 763.6202396.4 0.254
 Male 573.0184797.0
Marital status
 Married/partner 702.6258497.4 0.002
 Widowed/sep./div. 184.142195.9
 Never married 445.083195.0
Education
 High school 205.236694.8 0.015
 Completed HS 202.579197.5
 Some after sec. 563.9137796.1
 Univ. deg. 332.5130497.5
Employment status
 Full time 542.8190397.2 0.018
 Part time225.538094.5
 Other 563.4158696.6
Household income
 <20,000118.312191.7<0.001
 20–49,9993115.457994.9
 50–100,0003919.0104296.4
 >100,000312.6115297.4
ADHD previously diagnosed
 Yes2222.77577.3<0.001
 No1112.9378397.1
ASPD screen (≥4)
 ASPD1025.62974.4<0.001
 Non-ASPD1213.1379196.9
Psychiatric distress (GHQ-12)
 Yes (+3)6711.850288.2<0.001
 No (0–2)661.9336898.1
Ever treated with ADHD meds
 Yes615.03485.0<0.001
 No623.3180296.7
Antidepressant meds use
 Yes 
 No
48
85
17.5
2.3
227
3633
82.5
97.7
 <0.001
Anti-anxiety Meds Use
 Yes2719.611180.4<0.001
 No 422.4172597.6
Pain Meds Use (with and without pres.)
 Yes475.384394.7<0.001
 No852.8299697.2
AUDIT
 Yes (8+) 255.047795.00.039
 No (0–7) 1063.1329596.9
ASSIST
 Mod/High (4+) 157.718092.3<0.001
 Low (0–3) 1163.1367896.9
Lifetime used cannabis
Yes945.8152094.2<0.001
No 381.6232998.4
Past 12 mths cannabis use
Yes 387.348692.9 0.008
No942.7335297.3
Lifetime used cocaine
 Yes3211.325188.7<0.001
 No 1002.7360697.3
Ever arrested for a crime?
 Yes 237.528492.5<0.001
 No1103.0357397.0
Crash in past year
 Yes 136.020294.0 0.03
 No 1203.0386897.0

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.